JamesThrasherMDFellow American College of Endocrinology

Endocrinology • Little Rock, AR

Diabetes, Parathyroid, Thyroid

CEO, Endocrinologist, Arkansas Diabetes and Endocrinology Center

Join to view full profile

Dr. Thrasher is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Thrasher's full profile

Already have an account?

Office
11400 Huron Ln.
Little Rock, AR 72211
Phone+1 501-666-3666

Fax+1 501-907-9069
Is this information wrong?

Education & Training

University of Arkansas for Medical Sciences (UAMS) College of MedicineResidency, Internal Medicine, 1996 - 1999
University of Arkansas For Medical Sciences College of MedicineClass of 1996

Certifications & Licensure

AR State Medical License 1998 - 2024
MI State Medical License 2000 - 2004
American College of EndrocrinologyFellow of the American College of Endocrinology

Awards, Honors, & Recognition

Diabetes Recognition Program National Committee for Quality Assurance (NCQA)
Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2011
Fellow (FACE) American Association of Clinical Endocrinology

Clinical Trials

Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide) Start of enrollment: 2010 Jun 01
Completed
Phase 3
Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results Start of enrollment: 2010 Aug 31
Completed
Phase 3
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes Start of enrollment: 2010 Nov 11
Completed
Phase 3
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND) Start of enrollment: 2011 Jul 22
Completed
Phase 3
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin Start of enrollment: 2011 Dec 01
Completed
Phase 3
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy Start of enrollment: 2011 Dec 01
Completed
Phase 3
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy Start of enrollment: 2012 Aug 01
Completed
Phase 3
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus Start of enrollment: 2012 Sep 01
Completed
Phase 3
Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients Start of enrollment: 2013 Jun 01
Completed
Phase 3
A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events Start of enrollment: 2013 Oct 29
Completed
Phase 3
Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data Start of enrollment: 2013 Nov 26
Completed
Not Applicable
Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes Start of enrollment: 2014 Nov 11
Completed
Phase 3
Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine Start of enrollment: 2014 Oct 01
Completed
Phase 3
Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 2 Diabetes Mellitus Also Using Insulin Glargine Start of enrollment: 2015 Jan 01
Completed
Phase 3
Assessment of the Safety of SAR342434 and Humalog® When Administered as Continuous Subcutaneous Insulin Infusion Start of enrollment: 2015 Nov 01
Completed
Phase 1
A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes Start of enrollment: 2017 Jan 17
Completed
Phase 3
Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus Start of enrollment: 2017 Mar 15
Completed
Phase 3
A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes Start of enrollment: 2019 Jun 17
Active, not recruiting
Phase 3
Safety Evaluation of the Advanced Hybrid Closed Loop (AHCL) System Start of enrollment: 2019 Jul 24
Completed
Not Applicable
Cigarette Pack Inserts for Smoking Cessation Start of enrollment: 2019 Aug 01
Completed
Not Applicable
An Open-label, Two-center, Randomized, Cross-over Study to Evaluate the Safety and Efficacy of Glycemic Control Using Hybrid-closed Loop vs. Advanced Hybrid Closed-loop in Young Subjects With Type 1 Diabetes Start of enrollment: 2020 Jul 19
Completed
Not Applicable
Evaluation of the MiniMed™ 780G System in Type 1 Adult and Pediatric Subjects Utilizing Insulin Fiasp® Start of enrollment: 2022 Mar 17
Active, not recruiting
Not Applicable
In-Home Study With MiniMed™ 780G Pump Automated Control in Type 2-Evaluation of the AHCL System in Adults With Insulin-requiring Type 2 Diabetes Start of enrollment: 2022 Feb 25
Recruiting
Not Applicable
Join now to see all

Publications & Presentations

PubMed

Early Real-World Performance of the MiniMed™ 780G Advanced Hybrid Closed-Loop System and Recommended Settings Use in the United States.
Arrieta, A., Niu, F., Cameron, K., Cordero, T., Shin, J., Rhinehart, A., Thrasher, J., Vigersky, R.> ;Diabetes Technology & Therapeutics. 2024 Mar 1
Chapter 4: Summary and a Patient Perspective on Living with Heart Failure.
Monroe, R., Thrasher, J.> ;The American Journal of Medicine. 2024 Feb 1
4 citations
Safety and Glycemic Outcomes During the MiniMedAdvanced Hybrid Closed-Loop System Pivotal Trial in Children and Adolescents with Type 1 Diabetes.
Catherine Pihoker, Dorothy I Shulman, Gregory P Forlenza, Kevin B Kaiserman, Jennifer L Sherr, James R Thrasher, Bruce A Buckingham, Mark S Kipnes, Bruce W Bode, Ander...> ;Diabetes Technology & Therapeutics. 2023 Nov 1
9 citations
Glycemic Outcomes During Early Use of the MiniMed™ 780G Advanced Hybrid Closed-Loop System with Guardian™ 4 Sensor.
Toni L Cordero, Zheng Dai, Arcelia Arrieta, Fang Niu, Melissa Vella, John Shin, Andrew S Rhinehart, Jennifer McVean, Scott W Lee, Robert H Slover, Gregory P Forlenza, ...> ;Diabetes Technology & Therapeutics. 2023 Sep 1
12 citations
Evaluation of Extended Infusion Set Performance in Adults with Type 1 Diabetes: Infusion Set Survival Rate and Glycemic Outcomes from a Pivotal Trial.
Ron Brazg, Satish K Garg, Anuj Bhargava, James R Thrasher, Kashif Latif, Bruce W Bode, Timothy S Bailey, Barry S Horowitz, Arvind Cavale, Yogish C Kudva, Kevin B Kaise...> ;Diabetes Technology & Therapeutics. 2022 Aug 1
91 citations
Safety and Glycemic Outcomes During the MiniMed™ Advanced Hybrid Closed-Loop System Pivotal Trial in Adolescents and Adults with Type 1 Diabetes.
Anders L. Carlson, Jennifer L. Sherr, Dorothy I. Shulman, Satish K. Garg, Rodica Pop-Busui, Bruce W. Bode, David R. Lilenquist, Ron Brazg, Kevin B. Kaiserman, Mark Kip...> ;Diabetes Technology & Therapeutics. 2021 Nov 16
6 citations
Safety and Tolerability of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart (NovoLog) When Used in Insulin Pumps in Adults with Type 1 Diabetes: A ...
James Thrasher, Sarit Polsky, Lionel Hovsepian, Irene Nowotny, Suzanne Pierre, Béatrice Bois De Fer, Anuj Bhargava, Bhaswati Mukherjee, Satish K. Garg> ;Diabetes Technology & Therapeutics. 2020 Jan 28
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, Jeppesen OK, Lingvay I, Mosenzon O, Pedersen SD, Tack CJ, Thomsen M, Vilsbøll T, Warren ML, ...> ;The New England journal of medicine. 2019-06-11
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Riesmeyer JS, Riddle MC, Rydén L, Xavier D, Atisso CM, Dyal L, Hall S, Rao-Melacini ...> ;Lancet (London, England). 2019-06-09
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.
Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Botros FT, Riddle MC, Rydén L, Xavier D, Atisso CM, Dyal L, Hall S, Rao-Melacini P, ...> ;Lancet (London, England). 2019-06-07
177 citations
Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial.
Bernard Zinman, Vaishali Bhosekar, Robert S. Busch, Ingrid Holst, Bernhard Ludvik, Desirée Thielke, James Thrasher, Vincent Woo, Athena Philis-Tsimikas> ;The Lancet. Diabetes & Endocrinology. 2019 May 1
13 citations
Safety of Insulin Lispro and a Biosimilar Insulin Lispro When Administered Through an Insulin Pump.
James Thrasher, Howard Surks, Irene Nowotny, Suzanne Pierre, Baerbel Rotthaeuser, Karin Wernicke-Panten, Satish K. Garg> ;Journal of Diabetes Science and Technology. 2018 Jan 23
52 citations
Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies.
James Thrasher> ;The American Journal of Cardiology. 2017 Jul 1
73 citations
Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies
James Thrasher> ;The American Journal of Medicine. 2017 Jun 1
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, B...> ;N Engl J Med. 2016 Jul 28
Prevalence and Correlates of E-cigarette Perceptions and Trial Among Early Adolescents in Mexico
James F Thrasher, James D Sargent> ;Journal of Adolescent Health.
Hypoglycemia Reduction and Changes in Hemoglobin A1c in the ASPIRE In-Home Study.
Weiss R, Garg SK, Bode BW, Bailey TS, Ahmann AJ, Schultz KA, Welsh JB, Shin JJ> ;Diabetes Technol Ther. 2015 Aug
3 citations
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor linagliptin in black/African American patients with type 2 diabetes: Pooled analysis from eight Phase III t...
James Thrasher, David S Kountz, Susanne Crowe, Hans-Juergen Woerle, Maximilian von Eynatten> ;Postgraduate Medicine. 2015 Jun 3
10 citations
Predictors of Hypoglycemia in the ASPIRE In-Home Study and Effects of Automatic Suspension of Insulin Delivery
Ram Weiss, Satish K. Garg, Richard M. Bergenstal, David C. Klonoff, Bruce W. Bode, Timothy S. Bailey, James Thrasher, Frank L. Schwartz, John B. Welsh, Francine R. Kau...> ;Journal of Diabetes Science and Technology. 2015 May 18
New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naive people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled tria...
Bolli GB, Riddle MC, Bergenstal RM, Ziemen M, Sestakauskas K, Goyeau H, Home PD> ;Diabetes Obes Metab. 2015 Apr
New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in ...
Yki-Jarvinen H, Bergenstal R, Ziemen M, Wardecki M, Muehlen-Bartmer I, Boelle E, Riddle MC> ;Diabetes Care. 2014 Dec
3 citations
Insulin Lispro with Continuous Subcutaneous Insulin Infusion is Safe and Effective in Patients with Type 2 Diabetes: A Randomized Crossover Trial of Insulin Lispro Ver...
James Thrasher, Anuj Bhargava, Tina M. Rees, Tao Wang, Cristina B. Guzman, Leonard C. Glass> ;Endocrine Practice. 2015 Mar 1
Angiotensin-neprilysin inhibition versus enalapril in heart failure.
McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR> ;N Engl J Med. 2014 Sep 11
19 citations
Efficacy and Safety of Linagliptin in Black/African American Patients with Type 2 Diabetes: A 6-month, Randomized, Double-blind, Placebo-controlled Study.
James Thrasher, Kristen Daniels, Sanjay Patel, Jacqueline Whetteckey, Hans-Juergen Woerle> ;Endocrine Practice. 2014 May 1
Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rati...
McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau J, Shi VC, Solomon SD, Swedberg K, Zile MR> ;Eur J Heart Fail. 2013 Sep
Join now to see all

Press Mentions

Insulin Aspart Biosimilar Safe for Pump Therapy Use in Type 1 DiabetesFebruary 7th, 2020
New Real-World Data Shows MiniMed™ 780G System Sustains Strong Global Performance, Exceeding International Targets for Diabetes ManagementMarch 12th, 2024

Committees

Medtronic Hybrid Closed Loop (Artificial Pancreas) Studies Adult and Pediatric, Data Monitoring Board 2016 - 2022

Professional Memberships

Other Languages

French, German, Russian

Hospital Affiliations

CHI St. Vincent InfirmaryLittle Rock, Arkansas
Arkansas Heart HospitalLittle Rock, Arkansas

External Links

Facebookhttps://www.facebook.com/Arkansas-Diabetes-and-Endocrinology-Center-876051319176481/?ref=bookmarks
Websitehttps://www.adeclittlerock.com